Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Glucagon-like peptide 1 in health and disease

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. From conception to infancy - early risk factors for childhood obesity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Physical activity and muscle-brain crosstalk

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Improving pregnancy outcomes in women with diabetes mellitus: modern management

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Chronic endocrine consequences of traumatic brain injury - what is the evidence?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates insulin release and suppresses glucagon secretion in response to the ingestion of nutrients. GLP1 also delays gastric emptying and increases satiety. In patients with type 2 diabetes mellitus (T2DM), supraphysiological doses of GLP1 normalize the endogenous insulin response during a hyperglycaemic clamp. Owing to the short plasma half-life of native GLP1, several GLP1 receptor agonists (GLP1RAs) with longer half-lives have been developed for the treatment of T2DM. These compounds vary in chemical structure, pharmacokinetics and size, which results in different clinical effects on hyperglycaemia and body weight loss; these variations might also explain the difference in cardiovascular effect observed in large-scale cardiovascular outcome trials, in which certain GLP1RAs were shown to have a positive effect on cardiovascular outcomes. Owing to their metabolic effects, GLP1RAs are also considered for the treatment of several other lifestyle-induced conditions, such as obesity, prediabetes and liver disease. This Review provides insights into the physiology of GLP1 and its involvement in the pathophysiology of T2DM and an overview of the currently available and emerging GLP1RAs. Furthermore, we review the results from the currently available large-scale cardiovascular outcome trials and the use of GLP1RAs for other indications.

OriginalsprogEngelsk
TidsskriftNature reviews. Endocrinology
Vol/bind14
Sider (fra-til)390-403
Antal sider13
ISSN1759-5029
DOI
StatusUdgivet - maj 2018

ID: 53734239